12:00 AM
Oct 13, 2008
 |  BC Week In Review  |  Company News  |  Deals

Circassia, Ipsen deal

Circassia acquired from Ipsen North American and Japanese rights to develop and commercialize dopexamine. Circassia plans to develop the beta 2 adrenoreceptor and dopamine receptor...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >